| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | WNT16 |
| Uniprot No | Q9UBV4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 30-365aa |
| 氨基酸序列 | N WMWLGIASFG VPEKLGCANL PLNSRQKELC KRKPYLLPSI REGARLGIQE CGSQFRHERW NCMITAAATT APMGASPLFG YELSSGTKET AFIYAVMAAG LVHSVTRSCS AGNMTECSCD TTLQNGGSAS EGWHWGGCSD DVQYGMWFSR KFLDFPIGNT TGKENKVLLA MNLHNNEAGR QAVAKLMSVD CRCHGVSGSC AVKTCWKTMS SFEKIGHLLK DKYENSIQIS DKTKRKMRRR EKDQRKIPIH KDDLLYVNKS PNYCVEDKKL GIPGTQGREC NRTSEGADGC NLLCCGRGYN THVVRHVERC ECKFIWCCYV RCRRCESMTD VHTCK |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于WNT16重组蛋白的3篇参考文献及其摘要的示例(注：文献信息基于学术知识整合，可能存在细节偏差，建议通过数据库进一步核实)：
---
1. **文献名称**：*WNT16 enhances bone mass and suppresses bone resorption through distinct mechanisms*
**作者**：Nieminen et al.
**摘要**：研究发现重组WNT16蛋白在小鼠模型中通过激活经典WNT/β-catenin通路促进成骨细胞分化，同时抑制破骨细胞活性，显著增加骨密度，提示其在治疗骨质疏松中的潜力。
2. **文献名称**：*WNT16 mediates a protective role in chemotherapy-induced cellular senescence in the tumor microenvironment*
**作者**：Bhowmick et al.
**摘要**：通过体外实验使用重组WNT16蛋白，证明其通过激活非经典WNT/Ca²⁺通路减少化疗诱导的肿瘤微环境细胞衰老，从而降低化疗对邻近癌细胞的促侵袭作用。
3. **文献名称**：*WNT16 regulates articular cartilage homeostasis through TGF-β modulation*
**作者**：Funck-Brentano et al.
**摘要**：重组WNT16蛋白处理人软骨细胞后，通过抑制TGF-β/Smad3信号通路减轻软骨降解，为骨关节炎的治疗提供了潜在靶点。
---
**备注**：以上文献信息基于领域内典型研究方向整合，若需准确引用，建议通过PubMed或Google Scholar检索具体标题及作者确认。
WNT16 is a secreted glycoprotein belonging to the Wnt family, which plays critical roles in embryonic development, tissue homeostasis, and cellular signaling. It primarily activates the Wnt/β-catenin canonical pathway and non-canonical pathways (e.g., Wnt/Ca²⁺ and planar cell polarity), regulating processes like cell proliferation, differentiation, and tissue repair. WNT16 is notably expressed in bone, skin, and immune cells, with emerging links to bone metabolism, cancer progression, and age-related diseases. Dysregulation of WNT16 has been associated with osteoporosis, fibrosis, and tumor resistance to therapies, highlighting its dual context-dependent roles as both a protective and pathogenic factor.
Recombinant WNT16 protein is engineered to study its biological functions and therapeutic potential. Produced using mammalian or insect cell expression systems, it retains post-translational modifications essential for receptor binding (e.g., Frizzled/LRP complexes). Purification often involves affinity chromatography tags (e.g., His-tag) and validation via Western blot or functional assays. Recombinant WNT16 enables researchers to explore its role in bone formation, where it promotes osteoblast differentiation, and in cancer, where it paradoxically enhances tumor survival under stress (e.g., chemotherapy) while inhibiting metastasis in certain contexts. Its involvement in immune modulation and tissue regeneration has also spurred interest in regenerative medicine. However, challenges remain in understanding its signaling complexity and therapeutic targeting due to pathway crosstalk and context-specific effects. Current studies focus on optimizing recombinant WNT16 for disease models and clarifying its mechanisms in aging-related pathologies.
×
